• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ASTRO ’17 Round-up: Novocure touts five-year results for Optune, chemo combo in newly-diagnosed glioblastoma patients

September 25, 2017 By Sarah Faulkner

NovocureNovocure (NSDQ:NVCR) touted data today from the Phase III pivotal trial of its Optune device in combination with temozolomide for the treatment of newly-diagnosed glioblastoma.

The analyses were presented at the American Society for Radiation Oncology’s 2017 annual meeting in San Diego.

The company’s EF-14 trial showed unprecedented five-year survival results in patients with newly-diagnosed GBM, Novocure reported. Patients treated with the Optune-chemotherapy combination experienced a significant extension of overall survival, without added toxicity, compared to patients treated with just temozolomide.

Patients who received the combination therapy were also able to maintain quality of life for longer than those treated with just temozolomide, Novocure touted.

“As the first treatment in more than 10 years to improve overall survival in newly diagnosed GBM, Optune has been proven to make a difference in the lives of GBM patients,” Dr. Eilon Kirson, Novocure’s chief science officer & head of R&D, said in prepared remarks. “It is great to have Optune as a topic of discussion in radiation oncology.”

Novocure’s Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields”, to inhibit cancer cell replication.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Mayo Clinic, NovoCure, Royal Philips, viewray

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS